GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

GAL-101   Click here for help

GtoPdb Ligand ID: 14214

Synonyms: D-Trp-Aib [1] | GAL101 | MRZ-99030 [3]
Compound class: Peptide
Comment: GAL-101 (Galimedix Therapeutics) is a small bioactive peptide that reduces formation of neurotoxic amyloid β 1-42 (Aβ1-42) oligomers [1-3]. GAL-101 binds to aromatic residues in Aβ1-42 recognition interfaces during oligomer assembly and also breaks the protein's β strands [1]. This mechanism is proposed to reduce neuronal damage in Aβ-driven diseases.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CC(C)(C(=O)O)NC(=O)C(CC1=CNC2=C1C=CC=C2)N
Isomeric SMILES CC(C)(NC(=O)C(N)CC1=CNC2=C1C=CC=C2)C(O)=O
InChI InChI=1S/C15H19N3O3/c1-15(2,14(20)21)18-13(19)11(16)7-9-8-17-12-6-4-3-5-10(9)12/h3-6,8,11,17H,7,16H2,1-2H3,(H,18,19)(H,20,21)
InChI Key SHAXSXUDZJSSCN-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
GAL-101 is a clinical candidate for the treatment of age-related macular degeneration and Alzheimer's disease, which are characterised by elevated levels of Aβ1-42 aggregates in/around retinal ganglion cells and central neurons respectively.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06659549 A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD Phase 2 Interventional Galimedix Therapeutics Inc